Here are well-structured fourth-year PharmD research topic suggestions across all three categories:
π₯ General Medicine β Research Topics
1. Pharmacist-Led Medication Reconciliation at Hospital Transitions of Care
Focus: Evaluate the impact of pharmacist-driven medication reconciliation on reducing medication discrepancies and 30-day readmission rates in patients transitioning from hospital to home or skilled nursing facilities.
- Why it's relevant: Polypharmacy errors at care transitions are a leading cause of preventable adverse drug events.
- Methodology: Retrospective cohort or prospective interventional study comparing pre/post pharmacist involvement.
2. Clinical Pharmacist Interventions in Antibiotic Stewardship Programs (ASP)
Focus: Assess the role of pharmacist-led antibiotic stewardship in reducing inappropriate antibiotic prescribing, Clostridioides difficile infection rates, and antimicrobial resistance in inpatient settings.
- Why it's relevant: ASP is a core PharmD competency and a high-priority public health issue.
- Methodology: Retrospective chart review comparing antibiotic use pre/post stewardship implementation.
3. Pharmacist Impact on Glycemic Control in Type 2 Diabetes (Ambulatory Care)
Focus: Evaluate the effect of pharmacist-led medication therapy management (MTM) on HbA1c reduction, SGLT2 inhibitor/GLP-1 agonist adherence, and cardiovascular risk factor control in T2DM patients with CKD.
- Why it's relevant: Directly tied to evidence from CREDENCE and DAPA-CKD trials β high-impact, guideline-driven.
- Methodology: Randomized or quasi-experimental design in an outpatient clinic.
4. Deprescribing Potentially Inappropriate Medications (PIMs) in Elderly Patients
Focus: Assess the feasibility and outcomes of pharmacist-led deprescribing using the Beers Criteria or STOPP/START tool in hospitalized older adults.
- Why it's relevant: Polypharmacy in elderly patients is a growing patient safety concern.
- Methodology: Prospective interventional study with pre/post medication reviews.
π§ Psychiatry β Research Topics
1. Therapeutic Drug Monitoring (TDM) of Antipsychotics in First-Episode Psychosis
Focus: Evaluate the correlation between plasma levels of antipsychotics (e.g., risperidone, olanzapine, clozapine) and clinical outcomes (symptom control, side effects) using TDM in first-episode schizophrenia patients.
- Why it's relevant: Supported by the joint consensus of ASCP and AGNP on blood-level optimization (Management of First-Episode Psychosis, p.150).
- Methodology: Prospective observational study with TDM data and PANSS scoring.
2. Pharmacist Role in Monitoring and Managing Metabolic Side Effects of Antipsychotics
Focus: Assess pharmacist-led screening and intervention for antipsychotic-induced metabolic syndrome (weight gain, dyslipidemia, hyperglycemia) in outpatient psychiatric clinics.
- Why it's relevant: Metabolic adverse effects are the leading cause of antipsychotic non-adherence.
- Methodology: Chart review + patient survey; pre/post intervention design.
3. Medication Adherence in Bipolar Disorder: Impact of Pharmacist Counseling
Focus: Evaluate whether structured pharmacist counseling sessions improve adherence to mood stabilizers (lithium, valproate, lamotrigine) and reduce relapse rates in bipolar I/II patients.
- Methodology: Prospective interventional study using Morisky Medication Adherence Scale (MMAS-8).
4. Polypharmacy and Drug-Drug Interactions in Patients on Long-Acting Injectable (LAI) Antipsychotics
Focus: Identify the prevalence and clinical significance of drug-drug interactions in patients receiving LAI antipsychotics (e.g., paliperidone palmitate, aripiprazole lauroxil) in community mental health settings.
- Methodology: Retrospective database/chart review using an interaction checker tool (Lexicomp, Micromedex).
π€ Novel AI-Based Research Topics (PharmD Focus)
1. AI-Powered Clinical Decision Support for Pharmacist-Detected Drug Interactions
Focus: Develop or validate an AI/machine learning model trained on real-world EHR data to flag clinically significant drug-drug interactions in real time β comparing its performance to standard pharmacy software.
- Why it's novel: Goes beyond rule-based alerts; uses NLP and ML to prioritize alerts and reduce alert fatigue.
- Tools: Python (scikit-learn/XGBoost), hospital EHR data, FAERS database.
2. Natural Language Processing (NLP) for Adverse Drug Event Detection from Clinical Notes
Focus: Use NLP models (e.g., BERT, clinical BERT) to automatically extract and classify adverse drug events from unstructured physician/nursing notes in hospital EHRs.
- Why it's novel: Most ADEs go unreported through traditional systems; NLP enables passive surveillance.
- Tools: i2b2 NLP datasets, Python, HuggingFace Transformers.
3. AI-Based Prediction of Antipsychotic Treatment Response in Schizophrenia
Focus: Build a machine learning model that predicts likelihood of response or non-response to a specific antipsychotic based on patient demographics, genetics (if available), comorbidities, and early symptom trajectory.
- Why it's novel: Personalized antipsychotic selection remains largely trial-and-error; AI can enable precision psychiatry.
- Data sources: CATIE trial datasets, NIMH data repositories.
4. Large Language Model (LLM) Chatbot for Patient Medication Counseling: Accuracy and Safety Evaluation
Focus: Evaluate the accuracy, completeness, and safety of LLM-generated medication counseling responses (ChatGPT, Gemini, etc.) for common drugs compared to pharmacist-verified counseling β identifying gaps and hallucination risks.
- Why it's novel: Highly topical, publishable, and directly relevant to the future PharmD practice landscape.
- Methodology: Structured questionnaire design + expert panel review; no complex coding required β accessible for a 4th-year student.
5. Machine Learning to Predict 30-Day Hospital Readmissions in Polypharmacy Patients
Focus: Use ML algorithms (logistic regression, random forest, gradient boosting) to predict readmission risk in patients on β₯5 medications, with a focus on which drug-related problems (non-adherence, ADE, under-dosing) drive risk.
- Why it's novel: Positions the pharmacist as a data-informed, outcomes-driven clinician.
- Data sources: MIMIC-IV (publicly available critical care database).
Summary Table
| Category | Topic | Difficulty | Novelty |
|---|
| General Medicine | Medication Reconciliation at Transitions | ββ | β
β
β
|
| General Medicine | Antibiotic Stewardship Program | ββ | β
β
β
|
| General Medicine | Pharmacist MTM in T2DM + CKD | βββ | β
β
β
β
|
| General Medicine | Deprescribing PIMs in Elderly | ββ | β
β
β
|
| Psychiatry | TDM of Antipsychotics in First-Episode Psychosis | βββ | β
β
β
β
|
| Psychiatry | Antipsychotic Metabolic Side Effects | ββ | β
β
β
|
| Psychiatry | Adherence in Bipolar Disorder | ββ | β
β
β
|
| Psychiatry | Polypharmacy + DDIs with LAI Antipsychotics | ββ | β
β
β
|
| AI-Based | LLM Chatbot Accuracy for Medication Counseling | ββ | β
β
β
β
β
|
| AI-Based | NLP for ADR Detection from Clinical Notes | ββββ | β
β
β
β
β
|
| AI-Based | ML for Antipsychotic Response Prediction | ββββ | β
β
β
β
β
|
| AI-Based | AI-Based Drug Interaction Alert System | βββ | β
β
β
β
|
| AI-Based | ML for 30-Day Readmission in Polypharmacy | βββ | β
β
β
β
|
Top recommendation for a 4th-year PharmD student with manageable scope and high publishability:
- General Medicine: Pharmacist-led deprescribing using STOPP/START in elderly inpatients
- Psychiatry: TDM of antipsychotics in first-episode psychosis
- AI-Based: LLM chatbot accuracy evaluation for medication counseling β no advanced coding required, highly relevant, and publishable in pharmacy practice journals
Let me know if you'd like a full research proposal outline for any of these topics!